Background: Docetaxel, a semi-synthetic taxane may cause a usually mild sensory neuropathy. We describe the clinical characteristics of five patients who developed a more severe neuropathy following treatment with docetaxel.
Introduction
Docetaxel (Taxotere®) is a new semi-synthetic analogue of paclitaxel (Taxol®). In phase I and II clinical trials docetaxel has demonstrated clinical activity in a variety of tumors [1] . Neutropenia is the dose-limiting toxicity, other side-effects include hypersensitivity reactions, a fluid retention syndrome, gastrointestinal toxicity, skin toxicity and a usually mild and predominantly sensory axonal neuropathy. Occasionally docetaxel induces a more severe neuropathy, causing severe, painful paraesthesias and/or weakness. We found a moderate or severe neuropathy in 4 out of 15 patients treated with more than 600 mg/m 2 docetaxel [2] . To illustrate the clinical spectrum of more severe docetaxel neuropathy these patients are described, together with a woman who developed a sensory neuropathy after only one cycle. All patients received docetaxel at a dose of 100 mg/m 2 given as an 1-hour infusion repeated every three weeks, without corticosteroid pre-medication. They were all treated within clinical trials and underwent neurologic examinations at baseline and on regular intervals during and after treatment. None of these patients had diabetes mellitus or a history of alcoholism. Other patients characteristics, signs and symptoms, electrophysiological findings and course of the neuropathy are summarized in Table 1 .
Case reports
Patient A is a 71-year-old man with metastasized urothelial bladder cancer. Baseline neurological examination was normal, except for absence of ankle jerks. After three cycles he reported numbness and a heavy feeling in his feet. Eexamination showed loss of vibratory perception at his feet and loss of knee jerks. After six cycles he noted paraesthesias and numbness in his hands, and clumsiness. He showed some unsteadiness of gait and loss of joint position sense in his toes. Treatment was discontinued after nine cycles because of progressive neuropathy and severe edema, at that time the tumor was in complete remission. At examination a mild drop of both feet was present. In the next months he developed painful paraesthesias in his hands and legs. At the nadir of neuropathy he was unable to walk. He now had weakness of both legs, with proximal muscle strength MRC grade 3 and distal grade 4, a mild paresis of handmuscles and total areflexia. Hypaesthesia and absent vibratory perception was found below the knees and in his hands. Nerve conduction studies and EMG revealed a severe and mainly axonal neuropathy with abundant denervation potentials, with slight decrease of nerve conduction velocities. An abdominal CT-scan showed complete regression of para-aortal metastatic lymphnodes, a MRI-scan of the spine was normal. No other cause for the neuropathy than chemotherapy with docetaxel was found. Signs and symptoms gradually improved spontaneously. Five months after the last cycle pain had disappeared and he was able to walk unassisted. Ten months after the last cycle he was able to walk and bicycle for several hours. He is still doing well two years after the last cycle.
Patient B, a 60-year-old woman, developed livermetastases from ovarian cancer following treatment with cisplatin one year before. At baseline, neurological examination was normal. Chemotherapy was discontinued after the seventh cycle because of progressive disease. At that time she reported mild paraesthesias in her hands, her ankle jerks had disappeared. Paraesthesias subsequently progressed, and she developed numbness in hands and feet with loss of dexterity. Four months after the last cycle, loss of vibratory perception and joint position sense at her feet was found, a positive Romberg's sign and loss of knee jerks. At further followup these signs and symptoms improved. Nine months after the last cycle the patient reported normal dexterity, but still complained about paraesthesias. She died one year after the last cycle from progressive disease. Patient C, a 69-year-old man, was treated for metastasized bladder cancer with infiltration into the left lumbosacral plexus. At baseline neurological examination a mild paresis MRC grade 4 of the left foot dorsoflexors, absence of the left ankle jerk and hypaesthesia at the lateral foot were present. After four cycles he reported mild paraesthesias in his hands; at examination loss of vibratory perception at his toes and loss of tendon reflexes at his legs was found. Despite a partial tumor response, chemotherapy was discontinued after the seventh cycle because of severe paraesthesias in hands and feet, Lhermitte's sign and difficulty walking. At examination three weeks after the last cycle a paralysis of left foot dorso-flexors and MRC grade 3 weakness of foot flexors, complete areflexia and hypaesthesia of hands and lower legs was found. EMG and nerve conduction studies revealed a mainly sensory neuropathy and a lesion of the left ischiadic nerve. Progression of tumor was diagnosed in November 1993, thereafter the patient was lost to follow-up.
Patient D, a 47-year-old man was treated for a malignant pleural schwannoma following failure to ifosfamide and adriamycine. Before the start of docetaxel treatment he had no signs or symptoms of neuropathy. After two cycles he temporary felt paraesthesias in hands and feet. After four cycles, ankle jerks were lost and he had mild impairment of the joint position sense of his toes. The paraesthesias recurred after the sixth cycle. Docetaxel was stopped after six cycles because of progressive disease, but after that neuropathic symptoms increased. He developed painful paraesthesias, numbness, loss of dexterity and uncertainty with walking. Examination two months after the last cycle revealed impairment of vibratory perception and joint position sense at the feet, normal strength and loss of knee and ankle reflexes. Four months after the last cycle he died.
Patient E, a 31-year-old woman, developed livermetastases from breast cancer. After failure to cyclophosphamide and adriamycine, treatment was changed to docetaxel. Blood examination before the start of docetaxel treatment showed markedly elevated alkaline fosfatase, transaminases and gamma glutamyl transferase. Three days after the first cycle she noted numbness and a heavy feeling in both hands and legs which interfered with walking. Examination revealed hypaesthesia of her lower legs and hands, generalised areflexia and positive Romberg's sign. Nerve conduction studies showed slowing of sensory nerve conduction velocities. Because of neurotoxicity treatment was discontinued, after which the neuropathy improved. She died two months later.
Discussion
In phase I and II clinical trials on docetaxel, a mild dose-dependent and mainly sensory neuropathy has been observed [3] [4] [5] . In a phase II study on docetaxel conducted in our institution, 20 out of 41 evaluable patients treated with cumulative doses ranging 150-1100 mg/m 2 developed a usually mild neuropathy [2] . However, after treatment with a cumulative dose above 600 mg/m 2 , 4 out of 15 patients developed a moderate or severe predominant sensory neuropathy [2] . Paclitaxel causes a similar predominantly sensory axonal neuropathy which is related to both single dose and cumulative dose of the drug [6, 7] . Presumably, the neurotoxicity of both drugs is related to the promotion of microtubule aggregation in neurons, axons and Schwann cells [6] .
The clinical picture in our patients was dominated by sensory signs and symptoms, and started with paraesthesias and numbness in hands and feet. Loss of tendon reflexes and vibratory perception were early signs. With progression of neuropathy the paraesthesias became disabling or painful, suggesting involvement of small unmyelinated nerve fibres. Due to the numbness with loss of joint position sense several patients developed loss of dexterity and steadiness of gait. In contrast to cisplatin neuropathy, measurement of the vibration perception treshold was not a reliable indicator of neuropathy in these patients [2] . In patient A the neuropathy was accompanied by a predominantly proximal weakness leading to severe disability. New et al. found evidence of motor weakness in half of the patients with docetaxel neuropathy [8] . Another series reported in 7 out of 60 docetaxel-treated patients a predominantly proximal weakness [9] .
In most patients neuropathy appeared after two to four cycles. In general, signs and symptoms started shortly after administration of docetaxel, with some improvement before the next cycle but with a gradual progressing of neuropathy with new cycles. The decisive factor for docetaxel neuropathy appears to be the cumulative dose docetaxel but some patients have an individual susceptibility. None of our patients had diabetes mellitus nor did they use excessive amounts of alcohol. Patient E who developed a neuropathy after only one cycle had liver function abnormalities. Docetaxel clearance is reduced in patients with abnormal liver function, and the subsequent increase of the area under the concentration-time curve (AUC) has been related to an increase in side-effects [1] . Others suggested that shortinfusion paclitacxel treatment increases neurotoxicity, due to the increase in AUC in comparison to a 24-hour dosing schedule [10] .
In most patients with docetaxel neuropathy, symptoms improve in the weeks after treatment discontinuation [8] . In contrast, in three of our patients neuropathy progressed for several months after cessation of treatment. This phenomenon is also observed in cisplatin neuropathy [11, 12] . We did a similar observation in paclitaxel neuropathy [13] . It shows that recovery of taxoid-induced neuropathy following discontinuation of chemotherapy cannot be taken for granted. Still, in most patients the neuropathy was at least partly reversible.
Although paclitaxel and docetaxel neuropathy are mainly sensory axonal neuropathies, the electrophysiologic data in our patients and those of others suggest that in more severe cases of docetaxel neuropathy a mixed axonal-demyelinating neuropathy may develop [8] . The predominance of sensory features with onset simultaneously in hands and feet in many of our patients suggests that this neuropathy may not be a dying back, length-dependent neuropathy, but a neuronopathy primarily affecting the dorsal root ganglion [14] .
Lhermitte's sign is common with cisplatin neuropathy [15] . Since patient C we observed it in several other patients with docetaxel neuropathy [16] . In all, no other cause for Lhermitte's sign was found, and it disappeared following discontinuation of docetaxel chemotherapy.
In conclusion, neuropathy is not a predominant sideeffect of docetaxel [2, 8] . Routine neurologic evaluation does not seem useful, unless a patient develops signs of neurotoxicity. However, especially following treatment with a high cumulative dose, some patients may develop a severe and disabling neuropathy.
